marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2023
added 11-16-2024
GlaxoSmithKline plc Financial Ratios 2011-2024 | GSK
Annual Financial Ratios GlaxoSmithKline plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | - | 40.5 | 13.5 | 19.1 | 23.1 | 46.3 | 75.9 | 8.6 | 28.0 | 16.9 | 17.9 | 15.7 |
P/S |
- | - | 8.4 | 3.2 | 2.6 | 2.7 | 2.3 | 2.5 | 3.0 | 3.4 | 3.5 | 3.1 | 3.0 |
EPS |
- | - | 0.9 | 1.2 | 0.9 | 0.7 | 0.3 | 0.2 | 1.7 | - | - | - | - |
EV (Enterprise Value) |
43.3 B | 46.3 B | 260 B | 131 B | 145 B | 134 B | 14.1 B | 35.8 B | 55.2 B | 70.1 B | 91.2 B | 77.3 B | 81 B |
EBITDA per Share |
- | - | 1.24 | 3.15 | 2.81 | 2.23 | 1.67 | 3.21 | 1.76 | 2.41 | 3.03 | 3.1 | 3.44 |
EV/EBITDA |
33.1 | 13.1 | 11.0 | 8.6 | 9.7 | 10.2 | 18.8 | 15.3 | 14.7 | 12.7 | 11.3 | ||
PEG |
- | -5.48 | 0.64 | 1.43 | 5.68 | -14.99 | -0.85 | 0.04 | -0.57 | 0.8 | -1.6 | 0.07 | |
P/B |
- | - | 9.7 | 3.7 | 4.8 | 22.8 | 0.6 | 13.9 | 8.2 | 15.6 | 11.7 | 12.1 | 9.4 |
P/CF |
- | - | 26.0 | 9.2 | 11.1 | 9.9 | 10.2 | 22.9 | 149.3 | 30.9 | 22.7 | 39.2 | 23.0 |
ROE % |
- | - | - | 27.63 | 25.30 | 98.67 | 43.91 | 18.38 | 94.86 | 55.83 | 69.59 | 67.66 | 59.60 |
ROA % |
- | - | 6.44 | 7.15 | 5.83 | 6.24 | 2.72 | 1.54 | 15.76 | 6.78 | 12.92 | 11.01 | 12.81 |
ROCE % |
- | - | - | 13.35 | -36.78 | -19.42 | -17.90 | 7.72 | 3.93 | 7.98 | 10.59 | 11.15 | 12.87 |
Current Ratio |
1.3 | 1.2 | 1.4 | 1.3 | 1.3 | 1.1 | -1.1 | -0.9 | -1.2 | -1.1 | -1.1 | -1.0 | -1.1 |
DSO |
- | - | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | 200.5 | 194.4 | 210.9 | 165.8 | 183.5 | 192.8 |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 200.5 | 194.4 | 210.9 | 165.8 | 183.5 | 192.8 |
Cash Conversion Cycle |
- | - | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 200.5 | 194.4 | 210.9 | 165.8 | 183.5 | 192.8 |
All numbers in GBP currency
Quarterly Financial Ratios GlaxoSmithKline plc
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | - | 1.4 | - | - | - | 1.4 | - | - | - | 1.3 | - | - | - | 1.1 | - | - | - | 1.1 | - | - | - | 1.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in GBP currency